Elizabeth A. Mittendorf

Sep 12, 2024 | jamanetwork.com | Paolo Tarantino |Gabriel N. Hortobagyi |Sara M. Tolaney |Elizabeth A. Mittendorf

Heterogeneity of Residual Disease After Neoadjuvant Systemic Therapy in Breast Cancer: A Review Abstract Importance  Over the past 2 decades, systemic therapy for early-stage breast cancer has gradually moved from the adjuvant to the neoadjuvant setting. Administration of systemic therapy before surgery leads to potential improvements in surgical outcomes and allows for the assessment of the pathologic response to treatment.

Aug 29, 2024 | jamanetwork.com | Elizabeth A. Mittendorf |Sara M. Tolaney |Guillermo Villacampa |Víctor Navarro

Neoadjuvant Immunotherapy—From Trials to Practice Neoadjuvant Immune Checkpoint Inhibitors in Early Breast Cancer Guillermo Villacampa, MSc; Victor Navarro, MSc; Alexios Matikas, MD, PhD; Joana Mourato Ribeiro, MD; Francesco Schettini, MD, PhD; Pablo Tolosa, MD, PhD; Olga Martínez-Sáez, MD; Rodrigo Sánchez-Bayona, MD, PhD; Juan M.

Jun 24, 2024 | tandfonline.com | Sarah Beth Sammons |Elizabeth A. Mittendorf |Sara M. Tolaney |Ilana Schlam

ABSTRACTIntroduction Most patients with breast cancer have early-stage hormone receptor (HR)-positive, human epidermal growth factor receptor-2 (HER2)-negative disease. Even though the prognosis for most of these patients is good, there is a need to identify patients at risk for poor outcomes and to develop strategies to mitigate this risk.

Jun 14, 2023 | jamanetwork.com | Christina A. Minami |Rachel A. Freedman |Mara A. Schonberg |Elizabeth A. Mittendorf

The aging US population and increasing numbers of older adults with breast cancer highlight the need to determine how age-related syndromes, such as frailty, alter cancer outcomes and how cancer treatments change aging trajectories.

Mar 15, 2023 | jamanetwork.com | Christina A. Minami |Rachel A. Freedman |Mara A. Schonberg |Elizabeth A. Mittendorf

[Skip to Navigation] Table 1.  Patient Characteristics of Women Older Than 70 Years With DCIS or T1N0 HR-Positive and ERBB2-Positive Breast Cancer Who Underwent Locoregional TherapyTable 2.